Sexually Transmitted Infections

The FDA has approved Nuzolvence as a new single-dose oral option for uncomplicated urogenital gonorrhea in adults and children 12 years and older who weigh at least 77 lb.

Review some of the top stories from the Contemporary OB/GYN website over the past week and catch up on anything you may have missed.

Phase 3 results show oral zoliflodacin was non-inferior to ceftriaxone and azithromycin for uncomplicated urogenital gonorrhea.

This approval of gepotidacin is the first in a new antibiotic class for the treatment of gonorrhoea approved in over 3 decades.

Zoliflodacin study investigator Sarah McLeod, PhD, highlights data presented at IDWeek 2025 in a Q&A.

Universal EHR-based decision support eliminated racial disparities in adolescent chlamydia and gonorrhea testing in pediatric EDs.

Review some of the top stories from the Contemporary OB/GYN website over the past week and catch up on anything you may have missed.

FDA accepts priority review of gepotidacin, a first-in-class oral antibiotic, for treating uncomplicated urogenital gonorrhea in patients 12 years and older.

A new study finds that infections such as chlamydia, gonorrhea, and syphilis during pregnancy significantly increase the risk of stillbirth, preterm birth, and low birth weight.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

As strains of antibiotic-resistant gonorrhea spread, zoliflodacin provides an alternative oral treatment with non-inferiority to other methods.

The nearly 4000 cases in 2023 were the highest number reported in over 30 years, the Task Force stated.

A novel oral antibiotic, gepotidacin (Blujepa; GSK), has demonstrated its effectiveness in treating uncomplicated urogenital gonorrhea, according to the results of a recent phase 3 clinical trial.

A recent study highlights the genetic diversity within the ompA-genotype L2b clade, improving understanding of sexually transmitted infections and their transmission patterns.

The new panels, leveraging rapid polymerase chain reaction technology, allow point of care sexually transmitted infection diagnosis in 20 minutes, enhancing targeted treatment and reducing follow-up losses.

HPV vaccination in Brazil led to significant reductions in genital warts and cervical precancer hospitalizations, especially among those under 20 years of age.

The over-the-counter, at-home test provides blood results in 15 minutes that could help result in sooner syphilis diagnoses.

Adherence to guideline-based laboratory testing and treatment of chlamydia and gonorrhea in pregnant women has been found to be suboptimal in the United States, indicating the potential for negative effects on newborn and maternal health.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

A study presented at the Infectious Disease Society for Obstetrics and Gynecology 2024 Annual Meeting found an increase of 4 days between diagnosis and treatment among pregnant patients with congenital syphilis vs those without congenital syphilis.

A study presented at the Infectious Disease Society for Obstetrics and Gynecology 2024 Annual Meeting highlights the importance of affordability and convenience in boosting STI test uptake among adolescents and young adults.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

Following evidence from recent studies, the Centers for Disease Control and Prevention has recommended the use of doxycycline postexposure prophylaxis in sexual health among certain populations.

A recent study highlights the necessity of optimizing secondary prevention strategies to mitigate adverse cardiovascular outcomes in patients with HIV who face higher risks.

Despite WHO’s goals to reduce syphilis and other STI infections by 2030, rising case numbers underscore the urgent need for intensified global disease prevention and control efforts.